Beyond Greens/Gopal Partani & Co.

Wegovy 1mg Injection is a prescription medication containing the active ingredient semaglutide. It is a once-weekly subcutaneous (under the skin) injection used for long-term weight management in adults who are either obese (Body Mass Index or BMI of 30 or greater) or overweight (BMI of 27 or greater) with at least one weight-related health issue like high blood pressure, type 2 diabetes, or high cholesterol. It is also approved to reduce the risk of major cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with established heart disease who are also obese or overweight.

Wegovy is prescribed for long-term weight management in adults who are obese (Body Mass Index or BMI of 30 or greater) or overweight (BMI of 27 or greater) with at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol. It is also approved to reduce the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with established cardiovascular disease who are either overweight or obese. The medication is always used in conjunction with a reduced-calorie diet and increased physical activity.

Rybelsus 7mg is an oral tablet containing the active ingredient semaglutide. It is a prescription medication used along with diet and exercise to improve blood sugar control in adults with type 2 diabetes. The 7mg dose is a common maintenance dose, typically taken after a patient has been on the 3mg starting dose for at least 30 days.

Wegovy is an injectable prescription medicine used for chronic weight management. The active ingredient is semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is used in adults with obesity (a body mass index, or BMI, of 30 kg/m² or higher) or those who are overweight (a BMI of 27 kg/m² or higher) with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol. Wegovy is also approved to help reduce the risk of major cardiovascular events like heart attack and stroke in adults with established heart disease who are overweight or obese. It is meant to be used in addition to a reduced-calorie diet and increased physical activity.

Wegovy is an injectable prescription medicine that contains the active ingredient semaglutide. The 0.5 mg injection is part of a gradual dose escalation plan, typically used during weeks 5 to 8 of treatment. The medication is used in adults and adolescents aged 12 and older with obesity, or in some adults who are overweight with at least one weight-related health condition, to aid in weight loss and long-term weight management. It is also approved to reduce the risk of major cardiovascular events like heart attack, stroke, or death in adults with known heart disease and obesity or overweight.

Rybelsus 3mg is an oral tablet formulation of semaglutide, a medication primarily used for the management of type 2 diabetes. It is a once-daily prescription medicine that works as a glucagon-like peptide-1 (GLP-1) receptor agonist, meaning it mimics the action of a natural hormone in the body. Rybelsus is used in conjunction with a healthy diet and exercise to help adults with type 2 diabetes improve their blood sugar (glucose) control.

Rybelsus 14mg is an oral tablet formulation of semaglutide, a medication used for the treatment of type 2 diabetes. It is a once-daily prescription medication intended for use alongside a healthy diet and exercise to help adults with type 2 diabetes manage their blood sugar levels. The 14mg dose is the highest available and is typically reached after a patient has been on the 3mg and 7mg doses for at least 30 days each, allowing their body to adjust to the medication.

Orlistat is a lipase inhibitor. This means it works in the digestive system, specifically the stomach and small intestine, to block enzymes called lipases. These enzymes are responsible for breaking down dietary fats into a form that the body can absorb. By inhibiting these lipases, orlistat prevents about a third of the fat you eat from being digested and absorbed. The undigested fat is then passed out of the body in your stool. Because its action is local to the gut, very little of the drug is absorbed into the bloodstream.

Orlistat is a lipase inhibitor. This means it works in the digestive system, specifically the stomach and small intestine, to block enzymes called lipases. These enzymes are responsible for breaking down dietary fats into a form that the body can absorb. By inhibiting these lipases, orlistat prevents about a third of the fat you eat from being digested and absorbed. The undigested fat is then passed out of the body in your stool. Because its action is local to the gut, very little of the drug is absorbed into the bloodstream.

Orlistat is a lipase inhibitor. This means it works in the digestive system, specifically the stomach and small intestine, to block enzymes called lipases. These enzymes are responsible for breaking down dietary fats into a form that the body can absorb. By inhibiting these lipases, orlistat prevents about a third of the fat you eat from being digested and absorbed. The undigested fat is then passed out of the body in your stool. Because its action is local to the gut, very little of the drug is absorbed into the bloodstream.

Orliash Orlistat 120mg capsules are an anti-obesity medication used to aid in weight loss and weight management. The active ingredient, orlistat, is a lipase inhibitor that works in the stomach and small intestine by blocking the enzymes responsible for breaking down dietary fats. This prevents about 30% of the fat from the food you eat from being absorbed by your body. The undigested fat is then passed out through your stool. Orliash is intended for use in conjunction with a reduced-calorie, low-fat diet and regular physical activity.

Wegovy 2.4mg injection is the highest and recommended maintenance dose of the once-weekly, subcutaneous injection medication, semaglutide. It is used for long-term weight management in adults and adolescents aged 12 and older who are obese or overweight with at least one weight-related health condition. This medication is meant to be used in conjunction with a reduced-calorie diet and increased physical activity. It is also approved for reducing the risk of major cardiovascular events like heart attack, stroke, and cardiovascular death in adults with known heart disease who are also obese or overweight.